JPMorgan Chase & Co (XKAZ:JPM_KZ)
$ 246.38 1.38 (0.56%) Market Cap: 683.73 Bil Enterprise Value: 731.92 Bil PE Ratio: 13.85 PB Ratio: 2.16 GF Score: 2/100

United Therapeutics Corp Fireside Chat Hosted By JPMorgan Transcript

Jan 06, 2022 / 01:00PM GMT
Dewey Steadman
United Therapeutics Corporation - Head of IR

Good morning, everyone. I'm Dewey Steadman with United Therapeutics. And I'm happy today to present or to host or at least introduce Jessica Fye from JPMorgan who will be hosting our fireside chat with the management team today.

Before we start, I just want to remind you that we may make forward-looking statements today, and any risks and uncertainties are listed in our SEC filings, including Forms 10-K and 10-Q.

And with that, I'll turn it over to Jess.

Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Thanks, Dewey, and welcome, everyone. Happy New Year. I'm Jess Fye. I'm a biotech analyst at JPMorgan. Delighted to be joined today by United Therapeutics senior management team, including the company's Chairperson and CEO, Dr. Martine Rothblatt, as well as the company's President and COO, Michael Benkowitz. So thank you so much for spending this time with us this morning.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot